<DOC>
	<DOCNO>NCT02030301</DOCNO>
	<brief_summary>The purpose study test safety effectiveness two experimental therapeutic vaccine herpes simplex virus , type 2 ( HSV-2 ) .</brief_summary>
	<brief_title>Safety Efficacy Trial DNA Vaccines Treat Genital Herpes Adults</brief_title>
	<detailed_description>This dose escalation study evaluate safety , immunogenicity , efficacy 3 dos HSV plasmid DNA ( pDNA ) vaccine formulate VaxfectinÂ® subject minimum 1 year report history genital herpes , either 2 9 recurrence within year prior screening , 2 9 recurrence per year prior start suppressive therapy .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HSV2 seropositive A minimum 1 year report history genital herpes either 2 9 recurrence within year prior screen 2 9 recurrence per year prior start suppressive therapy History receive investigational HSV vaccine Chronic illness subject 's immune system suspect impaired altered , cancer , autoimmune condition , diabetes Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Herpes Simplex Virus , Type 2</keyword>
	<keyword>Herpes</keyword>
	<keyword>HSV-2</keyword>
</DOC>